$HUTCHMED(00013)$ 's partnership model is quite smart! Through the License-out model, the company collaborates with Takeda Pharmaceutical to handle the clinical development, production, and sales of its core product, Furmonertinib, in overseas markets.
This approach ensures that the income mainly comes from milestone payments and sales shares, rather than direct exports, making it immune to direct tariff impacts.
Additionally, after Furmonertinib was approved in the U.S. in 2024, it triggered a $35 million milestone payment, and its overseas sales grew by 134% year-over-year, demonstrating that this collaboration model effectively avoids trade barriers, making the future outlook very promising!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
